Options
Gt75 aptamer against eukaryotic elongation factor 1a as potential anticancer drug For castrate-resistant prostate cancer (crpc)
Scaggiante, Bruna
et al.
2014
Abstract
Prostate cancer diagnosis is increasing, being the second most frequently cancer in men
worldwide. The treatment of castrate-resistant prostate cancer is often unsuccessfully and new therapeutic
interventions are searching for. Nucleic acid aptamers targeting eEF1A proteins are emerging molecular tools
for the control of cancer growth. We found that an aptamer named GT75 was able to bind to eEF1A proteins
of human prostate cancer cell lines and to significantly and specifically reduce their growth with respect to
the control oligomer CT75. The highest anti-proliferation effect was found in the androgen-independent PC-3
cells. Interestingly, GT75 was able to specifically inhibit the migration of PC-3 cells but not that of the nontumorigenic
PZHPV-7 cells. The overall results suggest that the GT75 aptamer targeting eEF1A proteins is a
promising molecular drug to develop for the control of the castrate-resistant prostate cancer.
Publisher
EUT Edizioni Università di Trieste
Source
Bruna Scaggiante, Barbara Dapas, Alessandra Bosutti, Rossella Farra, Fabrizio Zanconati, Mario Grassi and Gabriele Grassi, Gt75 aptamer against eukaryotic elongation factor 1a as potential anticancer drug For castrate-resistant prostate cancer (crpc), in S. Passamonti, S. Gustincich, T. Lah Turnšek, B. Peterlin, R. Pišot, P. Storici (Eds.), Cross-border Italy-Slovenia biomedical research: are we ready for horizon 2020? Conference proceedings with an analysis of innovation management and knowledge transfer potential for a smart specialization strategy. Trieste, EUT Edizioni Università di Trieste, 2014, pp. 115-118
Languages
en
File(s)